Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

The Need for a Children's Oncology Group–Oriented Approach to Advance the Care of Children with Idiopathic Nephrotic Syndrome

John D. Mahan and William E. Smoyer
CJASN October 2009, 4 (10) 1549-1550; DOI: https://doi.org/10.2215/CJN.06060809
John D. Mahan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William E. Smoyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Idiopathic nephrotic syndrome (INS) affects 16 per 100,000 children, making this condition one of the most common childhood kidney diseases. Because of the significant complications associated with INS and its treatments in children, childhood INS remains a daunting challenge for children, families, and medical professionals. Amazingly, the approach to childhood INS today is still based on decades-old pivotal studies that were impressive in scope but have limited applicability to the clinical challenges faced by pediatric nephrologists today. These foundational studies began with an international collaborative effort sponsored by the International Study of Kidney Disease in Children (ISKDC) (1). From 1967 to 1974, 521 children with new-onset INS underwent renal biopsies and standard prednisone treatment to demonstrate that normalization of urine protein excretion with 8 wk of corticosteroid therapy is predictive of minimal-change nephrotic syndrome (2). As a result, pediatric nephrologists began using the initial therapeutic response to glucocorticoids to guide the subsequent evaluation and therapy for children who present with INS.

This sentinel work of the ISKDC was followed by a series of studies by the Arbeitsgemeinschaft für Pädiatrische Nephrologie, which together form the basis for modern practice treatment of children with INS (3–5). Of note, these landmark studies are also almost 20 yr old, but the clinical characteristics and challenges of children who present with INS have clearly changed in recent decades. For example, the incidence of FSGS in children with INS has increased dramatically (6); children in the United States have a rapidly increasing prevalence of obesity and type 2 diabetes, which may be exacerbated by our standard treatments with glucocorticoids (7); and the importance of demographic status and treatment compliance in patient outcomes is being increasingly recognized (8).

In 2008, a survey regarding treatment of childhood INS among North American pediatric nephrologists at 10 US centers was performed. That survey highlighted significant disparities among practitioners, including wide practice variations in even the most fundamental aspects of care, such as the management of initial presentations, relapses, and steroid resistance in children with INS (9). In this context, the North American Children's Nephrotic Syndrome Consensus Conference was convened to develop updated evidence- and opinion-based recommendations for the evaluation and treatment of children with INS for North American pediatric nephrologists (10). In that consensus conference report, only a limited number of treatment recommendations could be based on class 1 evidence; recommendations related to extent of evaluation, monitoring for complications, and treatment for steroid-dependent and steroid-resistant NS almost all were based on small case series and expert opinion. Of note, despite the 344 published original investigations reviewed during this process, only three of the 86 articles cited in that consensus conference report involved >10 yr of outcome follow-up in children with INS. This sobering reality emphasizes the value of the study of Kyrieleis et al. (11) in this month's CJASN, which addresses the long-term outcome of frequently relapsing minimal-change nephrotic syndrome in children and focuses on the effectiveness of continued immunosuppression and the complications of these agents in this population. In this report, at least 10 yr of follow-up is provided for all 15 patients with steroid-responsive INS that presented in childhood. All had at least one relapse after 16 yr of age, and the long follow-up offers insights into the ongoing treatment responsiveness in these children. Although this article indicates that corticosteroid responsiveness may persist for many years in some children, particularly in combination with second-line agents such as calcineurin inhibitors, complications are common and the risk-benefit ratios of treatments are unexplored. Although this report is only observational, it does reinforce the value and usefulness of detailed long-term observational studies of these children. Because the vast majority of our patients will survive to adulthood, there is a distinct need for studies of the long-term outcomes (and complications) of our therapies to help define the lifelong consequences of INS and its treatment in children. For too long, studies of treatment of children with INS have been limited to single centers and short-term perspectives, which inherently preclude us from gaining insight about important long-term issues.

One important take-home message from this article is the need for continued efforts to design and execute long-term studies that define the best evaluation and treatment strategies for children with INS. In light of the recent publications noted, the lack of good evidence and the need for prospective studies to determine the best current and future treatments for INS in children needs to be reemphasized. We believe that the only method to develop convincing evidence to drive future improvements in clinical care for these patients will be through careful prospective, multicenter, observational and interventional studies that address alternative treatment strategies and include comprehensive follow-up of children with INS. This process has been exceptionally productive for the Children's Oncology Group (COG) (http://www.curesearch.com) in the United States. This is a clinical trial cooperative group that is composed of investigators from 238 institutions that are supported by the National Cancer Institute to study childhood cancers (12). COG was formed in 2000 from the merger of four independent cooperative study groups, and it and its original members have been conducting prospective, randomized clinical trials since 1956 to study best treatments, quality of life, and impact of cost on families of children with cancer. Lessons learned from COG include (1) the power of sequential comparisons of novel versus standard-of-care treatments in prospective clinical trials to drive improvements in patient outcomes, (2) the critical importance of an established clinical trial infrastructure to enable repeated clinical trials with consistent and reliable participation among member centers, and (3) the essential need to combine patient results from multiple institutions to overcome the innate challenges of low patients numbers in pediatric studies. Although such efforts are extensive and the rewards will take time and patience, we believe that it will be through these types of prospective, multicenter, collaborative studies that we will be best able to advance the care of childhood INS, as well as other pediatric kidney diseases.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children,” on pages 1593–1600.

  • Copyright © 2009 by the American Society of Nephrology

References

  1. ↵
    1. Churg J,
    2. Habib R,
    3. White RH
    : Pathology of the nephrotic syndrome in children: A report for the International Study of Kidney Disease in Children. Lancet 760: 1299– 1302, 1970
    OpenUrlCrossRefPubMed
  2. ↵
    The primary nephrotic syndrome in children: Identification of patients with minimal change nephrotic syndrome from initial response to prednisone—A report of the International Study of Kidney Disease in Children. J Pediatr 98: 561– 564, 1981
    OpenUrlCrossRefPubMed
  3. ↵
    Alternate-day versus intermittent prednisone in frequently relapsing nephritic syndrome: A report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Lancet 1: 401– 403, 1979
    OpenUrlCrossRefPubMed
  4. ↵
    Short versus standard prednisone therapy for initial treatment of idiopathic nephritic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Lancet 1: 380– 383, 1988
    OpenUrlPubMed
  5. ↵
    1. Ehrich JH,
    2. Brodehl J
    : Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 152: 357– 361, 1993
    OpenUrlCrossRefPubMed
  6. ↵
    1. Srivastava T,
    2. Simon SD,
    3. Alon US
    : High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13: 13– 18, 1999
    OpenUrlCrossRefPubMed
  7. ↵
    1. Harris KM,
    2. Gordon-Larsen P,
    3. Chantala K,
    4. Udry JR
    : Longitudinal trends in race/ethnic disparities in leading health indicators from adolescence to young adulthood. Arch Pediatr Adolesc Med 160: 74– 81, 2006
    OpenUrlCrossRefPubMed
  8. ↵
    1. Fagot-Campagna A,
    2. Pettitt DJ,
    3. Engelgau MM,
    4. Burrows NR,
    5. Geiss LS,
    6. Valdez R,
    7. Beckles GL,
    8. Saaddine J,
    9. Gregg EW,
    10. Williamson DF,
    11. Narayan KM
    : Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr 136: 664– 672, 2000
    OpenUrlCrossRefPubMed
  9. ↵
    1. MacHardy N,
    2. Miles PV,
    3. Massengill SF,
    4. Smoyer WE,
    5. Mahan JD,
    6. Greenbaum L,
    7. Massie S,
    8. Yao L,
    9. Nagaraj S,
    10. Lin JJ,
    11. Wigfall D,
    12. Trachtman H,
    13. Hu Y,
    14. Gipson DS
    : Management patterns of childhood-onset nephrotic syndrome in the United States of America. Pediatr Nephrol 2009, in press
  10. ↵
    1. Gipson DS,
    2. MacHardy N,
    3. Massengill S,
    4. Smoyer WE,
    5. Mahan JD,
    6. Wigfall D,
    7. Miles P,
    8. Powell L,
    9. Lin JJ,
    10. Trachtman H,
    11. Greenbaum LA
    : Management of childhood onset nephrotic syndrome. Pediatrics 124: 747– 757, 2009
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kyrieleis HAC,
    2. Löwik MM,
    3. Pronk I,
    4. Cruysberg HRM,
    5. Kremer JAM,
    6. Oyen WJ,
    7. van den Heuvel BLP,
    8. Wetzels JFM,
    9. Levtchenko EN
    : Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 4: 1593– 1600, 2009
    OpenUrlAbstract/FREE Full Text
  12. ↵
    American Academy of Pediatrics Section on Hematology/Oncology Children's Oncology Group: Long-term follow-up care for pediatric cancer survivors. Pediatrics 123: 906– 915, 2009
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 4, Issue 10
1 Oct 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
The Need for a Children's Oncology Group–Oriented Approach to Advance the Care of Children with Idiopathic Nephrotic Syndrome
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Need for a Children's Oncology Group–Oriented Approach to Advance the Care of Children with Idiopathic Nephrotic Syndrome
John D. Mahan, William E. Smoyer
CJASN Oct 2009, 4 (10) 1549-1550; DOI: 10.2215/CJN.06060809

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Need for a Children's Oncology Group–Oriented Approach to Advance the Care of Children with Idiopathic Nephrotic Syndrome
John D. Mahan, William E. Smoyer
CJASN Oct 2009, 4 (10) 1549-1550; DOI: 10.2215/CJN.06060809
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Optimizing Utilization of Kidneys from Hepatitis C–Positive Kidney Donors
  • Mobile Health in Dialysis: The Best Engagement Medium Is the One that’s with Patients
  • Forever Starts Now
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire